Eli Lilly's Foundayo (Orforglipron) Launches at $25/Month for Insured Patients
Eli Lilly launched Foundayo on April 1 at $25/month for insured patients and $149 self-pay. The ATTAIN-1 trial showed 12.4% average body weight loss on the highest dose.
#orforglipron
15 stories
Foundayo vs. Oral Wegovy: Head-to-Head Oral GLP-1 Rivalry Heats Up
The ACHIEVE-3 trial in The Lancet showed Eli Lilly's Foundayo (orforglipron) superior on HbA1c, while Novo Nordisk's oral Wegovy may have an edge in weight-loss efficacy.
Comprehensive Review of Incretins: From Semaglutide to Orforglipron and Retatrutide
Psychiatric Times provides educational review of the incretin system covering the shift toward oral nonpeptide small-molecule GLP-1 RAs and triple agonists expected within 1-2 years.
Novo Nordisk Implements Strategic Pricing and Volume Growth Measures
Analysis covers Novo's competitive positioning including ORION study results comparing oral semaglutide against orforglipron, plus up to 48% price cuts in India.
FDA Approves Eli Lilly Oral GLP-1 Foundayo — Rivalry With Oral Wegovy Begins
Eli Lilly's Foundayo (orforglipron) won FDA approval with aggressive pricing as low as $25/month with savings card. Medicare Part D coverage could bring costs to $50/month starting July 2026.
FDA Approves Orforglipron: First GLP-1 Pill Without Food or Water Restrictions
Orforglipron (Foundayo) is the first GLP-1 pill that can be taken at any time without food or water restrictions, a major differentiator from oral semaglutide which requires morning dosing on an empty stomach.
Indirect Analysis: Oral Semaglutide May Beat Orforglipron on Weight Loss
Published the day after Foundayo's FDA approval, a new indirect comparison found oral semaglutide may produce greater weight loss than orforglipron with fewer GI discontinuations.
Foundayo vs Oral Wegovy: Head-to-Head Comparison Analysis
Managed Healthcare Executive compares Foundayo (orforglipron) vs oral Wegovy (semaglutide). ACHIEVE-3 trial data showed Foundayo superior on HbA1c, but oral Wegovy may edge ahead on weight loss.
Scientific American: How Eli Lilly's New GLP-1 Pill Foundayo Stacks Up Against Wegovy
In-depth comparison of Foundayo against existing GLP-1 drugs, noting 27 lbs average weight loss over 72 weeks at the highest dose. Experts hope more oral options will drive down costs and offer patients greater flexibility versus injectable regimens.
FDA Approves Foundayo Under National Priority Voucher Program in Record 50 Days
Foundayo became the first new molecular entity cleared under the Commissioner's National Priority Voucher Program, with review completed 294 days before the PDUFA date. Commercial pricing set at $25/month insured and $149/month self-pay at the lowest dose.
FDA Approves Eli Lilly's Foundayo (Orforglipron) as First Small-Molecule GLP-1 Pill for Obesity
The FDA approved Foundayo, a once-daily oral GLP-1 pill that can be taken any time without food or water restrictions. In trials, patients lost an average of 11% body weight over one year. It was approved under the FDA's National Priority Voucher program.
ATTAIN-MAINTAIN Trial Shows Orforglipron Maintains Weight Loss After Injectable Switch
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
Orforglipron FDA Decision Expected in April 2026
Eli Lilly's oral GLP-1 drug orforglipron is among the most consequential FDA decisions in Q2 2026. Analysts expect it to help Lilly's tirzepatide franchise exceed $100 billion in peak revenue.
Orforglipron and the Future of Oral GLP-1 Therapy
Pharmacy Times covers orforglipron's ability to cut A1C and drive meaningful weight loss with easier dosing than injections, potentially reshaping the GLP-1 treatment landscape.
Orforglipron Outperforms Oral Semaglutide in Phase 3 ACHIEVE-3 Trial
Eli Lilly's oral orforglipron demonstrated superior HbA1c reduction and weight loss vs oral semaglutide in Phase 3, strengthening the case ahead of an April FDA decision.